Categories: News

Sobi Q3 2025 report: Accelerated growth and portfolio momentum

STOCKHOLM, Oct. 20, 2025 /PRNewswire/ — Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2025

Third Quarter 2025

  • Total revenue increased 13 per cent, 21 per cent at constant exchange rates, (CER)1, to SEK 7,776 M (6,894)
  • Haematology revenue increased 26 per cent at CER to SEK 4,771 M (4,000), mainly driven by Altuvoct of SEK 769 M (129), strong sales of Doptelet of SEK 1,408 M (1,039) and sales of Aspaveli/Empaveli of SEK 317 M (270), somewhat offset by low Vonjo sales of SEK 307 M (379)
  • Immunology revenue increased 12 per cent at CER to SEK 2,658 M (2,583), driven by strong sales of Gamifant of SEK 733 M (405) and Kineret sales of SEK 769 M (699), somewhat offset by lower Beyfortus royalty of SEK 1,166 M (1,478)
  • Revenue from the strategic portfolio1* grew by 39 per cent at CER to SEK 5,001 M (3,830)
  • The product and marketing right Vonjo was impaired by SEK 6,612 M before tax. The impairment has not affected cash flow and is reported as items affecting comparability (IAC2)
  • The adjusted EBITA margin1,2 was 47 per cent (43), excluding IAC2 of SEK -6,664 M. EBITA1 was SEK 3,620 M (2,923), corresponding to a margin of 47 per cent (42). EBIT was SEK -3,858 M (2,038) including the impairment of Vonjo by SEK 6,612 M
  • Earnings per share (EPS) before dilution was SEK -8.40 (4.27) and EPS after dilution was SEK -8.32 (4.22). Adjusted EPS before dilution1 was SEK 6.11 (4.36) and adjusted EPS after dilution1 was SEK 6.05 (4.31). Cash flow from operating activities was SEK 1,840 M (1,201)

Outlook 2025 – updated

  • Revenue is anticipated to grow at low double-digit percentage at CER
    (previously high-single-digit)
  • Adjusted EBITA margin adjusted is anticipated to be at mid-to-high 30s percentage of revenue
    (previously mid-30s)

Financial summary



SEK M

Read moreFossil launches its first smartwatch on the Qualcomm Snapdragon Wear 3100 platform



Q3
2025



Q3
2024



Change



Jan-Sep
2025



Jan-Sep
2024

Read moreConwy Care Home Multi-Professional Response wins Secure I.T. Environments Sponsored award at Betsi Cadwaladr University Health Board Achievement Awards



Change



FY
2024

Total revenue 

7,776

6,894

Read moreTorus and Aareon Collaborate on Housing Management Solution

13 %

20,417

18,592

10 %

26,027

Gross profit 

6,162

5,563

11 %

15,788

14,407

10 %

20,242

Gross margin1 

79 %

81 %

77 %

77 %

78 %

Adjusted gross margin1,2 

80 %

81 %

78 %

78 %

78 %

EBITA1 

3,620

2,923

24 %

7,743

6,585

18 %

9,158

Adjusted EBITA1,2 

3,672

2,965

24 %

8,124

6,811

19 %

9,368

EBITA margin1 

47 %

42 %

38 %

35 %

35 %

Adjusted EBITA margin1,2 

47 %

43 %

40 %

37 %

36 %

Profit/loss for the period 

-2,895

1,464

>-200%

-1,386

2,488

-156 %

3,879

EPS before dilution, SEK 

-8.40

4.27

>-200%

-4.02

7.29

-155 %

11.37

Adjusted EPS before dilution, SEK1,2 

6.11

4.36

40 %

11.25

7.80

44 %

11.83

EPS after dilution, SEK 

-8.32

4.22

>-200%

-3.99

7.21

-155 %

11.24

Adjusted EPS after dilution, SEK1,2 

6.05

4.31

40 %

11.14

7.71

45 %

11.69

  1. Alternative Performance Measures (APMs)
  2. Items affecting comparability (IAC)

* The strategic portfolio includes Sobi’s medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant, Vonjo and Zynlonta, and royalty on Sanofi’s sales of Altuviiio and Beyfortus.

Investors, analysts, and the media are invited to a conference call on the same day at 13:00 CEST, 12:00 BST, and 07:00 EDT. The call will include a presentation of the results and a Q&A session.

The presentation can be followed live here or afterwards on sobi.com. The slides will be made available on sobi.com before the conference call.

To participate in the conference call, please use the following dial-in details:
Sweden: +46 8 5051 0031
United Kingdom: +44 207 107 06 13
United States: +1 631 570 56 13

For other countries, please find the details here.

For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here.

This information is information that Sobi is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08:00 CEST on 20 October 2025.

Gerard Tobin
Head of Investor Relations

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/swedish-orphan-biovitrum-ab/r/sobi-q3-2025-report–accelerated-growth-and-portfolio-momentum,c4252738

The following files are available for download:


https://mb.cision.com/Main/14266/4252738/3730526.pdf

Q3 2025 report. Accelerated growth and portfolio momentum

 

View original content:https://www.prnewswire.com/news-releases/sobi-q3-2025-report-accelerated-growth-and-portfolio-momentum-302588812.html

SOURCE Swedish Orphan Biovitrum AB

Staff

Share
Published by
Staff
2 months ago

Recent Posts

Restart Life Sciences Announces Closing First Tranche of Financing

Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

17 minutes ago

TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg

Vancouver, British Columbia--(Newsfile Corp. - December 5, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) (FSE:…

17 minutes ago

Correction to MyndTec Inc. Press Release Issued December 3, 2025 Regarding Non-Brokered Private Placement

Mississauga, Ontario--(Newsfile Corp. - December 5, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), announced…

17 minutes ago

Atropos Health Expands Oncology Precision Medicine Capabilities with Publication of New AI Algorithms for Rare Disease and Integration of ASCO Guidelines

Atropos Health is integrating the American Society of Clinical Oncology® (ASCO®) Guidelines into their platform…

5 hours ago

USF and Old Dominion to Play in the 2025 StaffDNA Cure Bowl

PLANO, Texas, Dec. 5, 2025 /PRNewswire/ -- Teams playing in the StaffDNA® Cure Bowl were…

5 hours ago

The Dot Corp Expands Services With New Promotional Products & Apparel Division

IRVINE, Calif., Dec. 5, 2025 /PRNewswire/ -- The Dot Corp has expanded its services with…

5 hours ago